Abvc Biopharma annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Abvc Biopharma Debt-to-Equity Ratio Growth & History (ABVC)
Abvc Biopharma's debt-to-equity ratio was 0.24 for fiscal 2025.
View full Abvc Biopharma company overviewAbvc Biopharma annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.24 | −1.06 | −81.45% |
| 2024 | 2024-12-31 | 1.30 | 0.41 | +46.21% |
| 2023 | 2023-12-31 | 0.89 | 0.21 | +30.45% |
| 2022 | 2022-12-31 | 0.68 | 0.46 | +202.66% |
| 2021 | 2021-12-31 | 0.22 | −0.34 | −60.28% |
| 2020 | 2020-12-31 | 0.57 | — | — |
Abvc Biopharma quarterly debt-to-equity ratio
Q3.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.18 | 0.08 | +74.20% |
| Q1 2026 | 2026-03-31 | 0.18 | −0.07 | −27.39% |
| Q4 2025 | 2025-12-31 | 0.24 | −1.06 | −81.45% |
| Q3 2025 | 2025-09-30 | 0.10 | −0.76 | −88.57% |
| Q2 2025 | 2025-06-30 | 0.10 | −0.77 | −88.38% |
| Q1 2025 | 2025-03-31 | 0.25 | −0.67 | −72.93% |
| Q4 2024 | 2024-12-31 | 1.30 | 0.41 | +46.21% |
| Q3 2024 | 2024-09-30 | 0.85 | 0.74 | +629.86% |
| Q2 2024 | 2024-06-30 | 0.88 | — | — |
| Q1 2024 · Mar 31 | 2024-03-31 | 0.91 | 0.24 | +36.63% |
| Q4 2023 | 2023-12-31 | 0.89 | 0.21 | +30.45% |
| Q3 2023 | 2023-09-30 | 0.12 | −0.26 | −68.91% |
| Q1 2023 | 2023-03-31 | 0.67 | 0.40 | +153.19% |
| Q4 2022 | 2022-12-31 | 0.68 | 0.46 | +202.66% |
| Q3 2022 | 2022-09-30 | 0.38 | 0.20 | +108.33% |
| Q2 2022 | 2022-06-30 | 0.21 | −2.07 | −90.93% |
| Q1 2022 | 2022-03-31 | 0.26 | −1.03 | −79.63% |
| Q4 2021 | 2021-12-31 | 0.22 | −0.34 | −60.28% |
| Q3 2021 | 2021-09-30 | 0.18 | — | — |
| Q2 2021 | 2021-06-30 | 2.27 | — | — |
| Q1 2021 | 2021-03-31 | 1.29 | — | — |
| Q4 2020 | 2020-12-31 | 0.57 | — | — |
| Q3 2019 | 2019-09-30 | 1.79 | — | — |
Abvc Biopharma debt-to-equity ratio trends
Over the last five fiscal years, Abvc Biopharma's debt-to-equity ratio decreased from 0.57 to 0.24, a change of −0.33. The latest reported quarter, Q2 2026, shows 0.18.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abvc Biopharma source filings ↗